CoChat

The incretins: a link between nutrients and well-being

Open access
Burcelin, Rémy · 2005 · British Journal of Nutrition
Cited by 70

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

The glucoincretins, glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP), are intestinal peptides secreted in response to glucose or lipid intake. Data on isolated intestinal tissues, dietary treatments and knockout mice strongly suggest that GIP and GLP-1 secretion requires glucose and lipid metabolism by intestinal cells. However, incretin secretion can also be induced by non-digestible carbohydrates and involves the autonomic nervous system and endocrine factors such as GIP itself and cholecystokinin. The classical pharmacological approach and the recent use of knockout mice for the incretin receptors have shown that a remarkable feature of incretins is the ability to stimulate insulin secretion in the presence of hyperglycaemia only, hence avoiding any hypoglycaemic episode. This important role is the basis of ongoing clinical trials using GLP-1 analogues. Since most of the data concern GLP-1, we will focus on this incretin. In addition, GLP-1 is involved in glucose sensing by the autonomic nervous system of the hepato-portal vein controlling muscle glucose utilization and indirectly insulin secretion. GLP-1 has been shown to decrease glucagon secretion, food intake and gastric emptying, preventing excessive hyperglycaemia and overfeeding. Another remarkable feature of GLP-1 is its secretion by the brain. Recently, elegant data showed that cerebral GLP-1 is involved in cognition and memory. Experiments using knockout mice suggest that the lack of the GIP receptor prevents diet-induced obesity. Consequently, macronutrients controlling intestinal glucose and lipid metabolism would control incretin secretion and would consequently be beneficial for health. The control of incretin secretion represents a major goal for new therapeutic as well as nutrition strategies for treating and/or reducing the risk of hyperglycaemic syndromes, excessive body weight and thus improvement of well-being.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1079/bjn20041340

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 120

  1. 10.1177/000456328902600214 · DOI
  2. Widmann, 1994, Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of beta cell lines, Mol Pharmacol, 45, 1029
  3. 10.1172/JCI117671 · DOI · Paper page
  4. 10.1016/0014-5793(94)00553-2 · DOI · Paper page
  5. 10.1016/0143-4179(92)90036-V · DOI
  6. 10.2337/diab.43.6.752 · DOI
  7. 10.1016/0006-8993(83)91332-X · DOI · Paper page
  8. 10.1016/0167-0115(88)90037-7 · DOI
  9. Schmitt, 1973, Influence of hepatic portal receptors on hypothalamic feeding and satiety centers, Am J Physiol, 225, 1089, 10.1152/ajplegacy.1973.225.5.1089 · DOI · Paper page
  10. 10.1172/JCI118411 · DOI · Paper page
  11. 10.1074/jbc.270.44.26488 · DOI · Paper page
  12. 10.1073/pnas.91.8.3242 · DOI · Paper page
  13. 10.1053/meta.2000.6251 · DOI
  14. 10.1210/endo.137.6.8641190 · doi:10.1210/endo.137.6.8641190 · Paper page
  15. 10.1210/endo.137.9.8756571 · doi:10.1210/endo.137.9.8756571 · Paper page
  16. 10.1172/JCI118410 · DOI · Paper page
  17. 10.2337/diab.40.12.1659 · DOI · Paper page
  18. 10.1038/247284a0 · DOI · Paper page
  19. 10.1038/222282a0 · DOI · Paper page
  20. Oomura, 1981, Chemosensitive neuron in the hypothalamus related to food intake behavior, Jpn J Pharmacol, 31, 1P, 10.1016/S0021-5198(19)54826-0 · doi:10.1016/s0021-5198(19)54826-0
  21. 10.1093/ajcn/53.1.155 · DOI
  22. 10.1113/jphysiol.1985.sp015733 · DOI
  23. 10.1210/endo.138.10.5574 · doi:10.1210/endo.138.10.5574 · Paper page
  24. Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J Clin Endocrinol Metab, 76, 912
  25. Nauck, 1996, Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes, Diabet Med, 13, S39
  26. Moore, 1996, Neural and pancreatic influences on net hepatic glucose uptake and glycogen synthesis, Am J Physiol, 271, E215
  27. 10.1016/S0899-9007(97)85073-4 · doi:10.1016/s0899-9007(97)85073-4
  28. 10.1016/0014-5793(84)81114-X · DOI · Paper page
  29. 10.1016/0006-8993(89)90628-8 · DOI
  30. 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
  31. 10.2337/diab.38.7.902 · DOI · Paper page
  32. 10.2337/diab.44.1.16 · DOI · Paper page
  33. 10.1002/(SICI)1099-1263(199801/02)18:1<47::AID-JAT474>3.0.CO;2-S · doi:10.1002/(sici)1099-1263(199801/02)18:1<47::aid-jat474>3.0.co;2-s
  34. Jehle, 1995, Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding, Exp Clin Endocrinol Diabetes, 2, 31
  35. 10.1016/0026-0495(93)90037-O · DOI
  36. 10.1038/361362a0 · DOI · Paper page
  37. 10.1016/0014-5793(87)81430-8 · DOI · Paper page
  38. 10.1016/0016-5085(94)90831-1 · DOI · Paper page
  39. 10.2337/diabetes.49.1.8 · DOI · Paper page
  40. 10.2337/diab.46.9.1521 · DOI · Paper page
  41. 10.1677/joe.0.1470025 · DOI · Paper page
  42. 10.1016/0026-0495(95)90021-7 · DOI
  43. 10.1152/ajpgi.2000.278.6.G924 · DOI · Paper page
  44. 10.1007/BF02576216 · DOI
  45. Goke, 1997, The intestinal hormone glucagon-like peptide 1 (GLP-1): from experiment to the clinic, Z Gastroenterol, 35, 285
  46. 10.1016/0014-5793(86)80697-4 · DOI · Paper page
  47. 10.1677/jme.0.0100259 · DOI · Paper page
  48. 10.1016/S0006-8993(97)00190-X · DOI
  49. 10.2337/diab.42.9.1253 · DOI · Paper page
  50. Fridolf, 1991, GLP-1(7–36) amide stimulates insulin secretion in rat islets: studies on the mode of action, Diabetes Res, 16, 185
  51. 10.1016/0167-4889(91)90200-H · DOI
  52. 10.1016/S0006-8993(97)01057-3 · DOI · Paper page
  53. 10.1007/s004419900093 · DOI
  54. 10.2337/diacare.19.6.580 · DOI · Paper page
  55. Creutzfeldt, 1992, Entero-insular axis and diabetes mellitus, Horm Metab Res, 26, 13
  56. 10.1210/endo.134.5.8156917 · doi:10.1210/endo.134.5.8156917 · Paper page
  57. 10.1002/(SICI)1096-9136(199610)13:10<854::AID-DIA262>3.0.CO;2-E · DOI
  58. 10.2337/diabetes.50.8.1720 · DOI · Paper page
  59. 10.2337/diabetes.49.10.1643 · DOI · Paper page
  60. 10.1111/j.1749-6632.1999.tb08510.x · DOI
  61. 10.2337/diabetes.50.6.1282 · DOI · Paper page
  62. 10.1007/BF00492251 · DOI · Paper page
  63. 10.1210/endo-123-4-2009 · DOI · Paper page
  64. 10.1210/endo-128-6-3175 · DOI · Paper page
  65. Brown, 1970, A multiparameter study on the action of preparations containing cholecystokinin pancreozymin, Scand J Gastroenterol, 5, 537, 10.1080/00365521.1970.12096632 · DOI · Paper page
  66. 10.1139/o71-037 · DOI · Paper page
  67. 10.1007/BF02914270 · DOI
  68. 10.2337/diab.38.1.7 · DOI · Paper page
  69. 10.1016/0165-1838(83)90039-5 · DOI
  70. Banting, 1922, The internal secretion of the pancreas, J Lab Clin Med, 7, 251
  71. Balkan, 2000, Portal GLP1 administration in rats augments the insulin response to glucose via neuronal mechanisms, Am J Physiol, 279, R1449
  72. Holst, 1996, GLP-1 in NIDDM, Diabet Med, 13, S156, 10.1002/dme.1996.13.s6.156 · doi:10.1002/dme.1996.13.s6.156
  73. 10.1046/j.1471-4159.1996.66030920.x · DOI · Paper page
  74. 10.1016/S0014-2999(00)00600-2 · DOI · Paper page
  75. Ahrén, 1997, Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus, J Clin Endocrinol Metab, 82, 473
  76. 10.1152/ajpregu.00423.2003 · DOI · Paper page
  77. 10.1016/S0026-0495(96)90066-9 · DOI
  78. 10.1007/BF00745145 · DOI
  79. 10.1007/BF00581038 · DOI
  80. 10.1007/s005920050059 · DOI
  81. 10.2337/diab.42.11.1678 · DOI · Paper page
  82. 10.2337/diab.42.9.1219 · DOI · Paper page
  83. 10.1210/endo-111-5-1601 · DOI · Paper page
  84. Ahrén, 1999, Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice, Am J Physiol, 277, E996
  85. 10.1016/S0014-5793(97)00254-8 · DOI
  86. Orskov, 1987, Pancreatic and intestinal processing of proglucagon in man, Diabetologia, 30, 874, 10.1007/BF00274797 · DOI · Paper page
  87. 10.1016/S0026-0495(96)90192-4 · DOI
  88. 10.1016/0014-5793(88)81063-9 · DOI · Paper page
  89. 10.1093/jn/128.7.1099 · DOI
  90. 10.1146/annurev.physiol.59.1.257 · DOI · Paper page
  91. 10.2337/diab.47.2.159 · DOI · Paper page
  92. 10.1007/s001250051347 · DOI
  93. Nakabayashi, 1996, Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1, Am J Physiol, 271, E808
  94. 10.1172/JCI112855 · DOI · Paper page
  95. 10.1016/0742-8413(95)00046-1 · DOI
  96. 10.1016/0167-0115(93)90137-W · DOI
  97. Balks, 1997, Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors, J Clin Endocrinol Metab, 82, 786
  98. 10.2337/diab.43.4.535 · DOI · Paper page
  99. 10.1113/jphysiol.1902.sp000920 · DOI · Paper page
  100. Goke, 1989, Signal transmission after GLP-1(7–36)amide binding in RINm5F cells, Am J Physiol, 257, G397
  101. 10.1530/eje.0.1350425 · DOI · Paper page
  102. 10.1210/endo.136.12.7588313 · doi:10.1210/endo.136.12.7588313 · Paper page
  103. 10.1016/0304-3940(84)90444-0 · DOI · Paper page
  104. 10.1210/endo-121-3-1076 · DOI · Paper page
  105. 10.1016/0168-8227(92)90024-L · DOI
  106. 10.1007/BF00417698 · DOI
  107. 10.1111/j.1749-6632.1969.tb12914.x · DOI · Paper page
  108. 10.1073/pnas.84.20.7005 · DOI · Paper page
  109. 10.1006/bbrc.2000.2288 · DOI
  110. Thiele, 1997, Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats, Am J Physiol, 272, R726
  111. 10.1097/00006676-199005000-00019 · DOI
  112. 10.1097/00006676-199007000-00018 · DOI · Paper page
  113. 10.2337/diab.44.9.1126 · DOI · Paper page
  114. 10.1111/j.1464-5491.1993.tb01995.x · DOI · Paper page
  115. 10.1210/endo.140.4.6643 · doi:10.1210/endo.140.4.6643 · Paper page
  116. 10.1054/npep.1999.0053 · DOI
  117. 10.3109/00365529609009147 · DOI · Paper page
  118. 10.1038/nm0903-1113 · DOI
  119. Nauck, 1996, Release of glucagon-like peptide 1 (GLP-1 [7–36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections, Z Gastroenterol, 34, 159
  120. 10.1677/joe.0.1450521 · DOI · Paper page

Cited by

See all 70

Metadata

Authors
Burcelin, R.
Venue
British Journal of Nutrition
Published
2005-04
Volume
93
Issue
S1
Pages
S147-S156
ISSN
  • 0007-1145 (ISSN-L)
  • 1475-2662
OpenAlex
W1984290796
Cited by
70
References
28
FWCI
3.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The incretins: a link between nutrients and well-being. https://app.cochat.ai/papers/10.1079/bjn20041340
The paper
Burcelin, R. (2005). The incretins: a link between nutrients and well-being. British Journal of Nutrition. https://doi.org/10.1079/bjn20041340

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.